Comparing clinical outcomes between patients with urothelial carcinoma who treated neoadjuvant chemotherapy by gemcitabine-cisplatin and dose dense MVAC.

被引：0
|
作者：
Lee, Yongjune
Kim, Young Seok
Hong, Bumsik
Cho, Yong Mee
Lee, Jae-Lyun
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiat Oncol, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Urol, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea
[5] Asan Med Ctr, Seoul, South Korea
[6] Univ Ulsan, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.376
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
376
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy
    Robins, Dennis
    Matulay, Justin
    Lipsky, Michael
    Meyer, Alexa
    Ghandour, Rashed
    DeCastro, Guarionex
    Anderson, Christopher
    Drake, Charles
    Benson, Mitchell
    McKiernan, James M.
    UROLOGY, 2018, 111 : 116 - 121
  • [42] Association of presurgery neutrophil-to-lymphocyte ratio with survival outcomes in patients with urothelial carcinoma treated without neoadjuvant chemotherapy and with radical cystectomy.
    Kukreja, Janet Baack
    Podolnick, Jason M.
    Wang, Xuemei
    Chen, Hsiang-Chun
    Navai, Neema
    Kamat, Ashish M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [43] NEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) plus durvalumab plus /- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
    Thibault, C.
    Audenet, F.
    Borchiellini, D.
    Huillard, O.
    Barthelemy, P.
    Pouessel, D.
    Flechon, A.
    Blons, H.
    Sautes-Fridman, C.
    Sun, C-M.
    Verkarre, V.
    Pallet, N.
    Mejean, A.
    Rouabah, M.
    Helali, I.
    Elaidi, R-T.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [44] Feasibility and efficacy of neoadjuvant chemotherapy with dose-dense methotrexate, vinblastine, adriamycin, and cisplatin (M-VAC) in patients with high-grade urothelial cancer with muscle invasion.
    Elmongy, M. B.
    Kaag, M.
    Reese, C. T.
    Algood, C. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] Imact of KRAS mutation on clinical outcomes in pancreatic cancer patients who were treated with first-line gemcitabine-based chemotherapy
    Park, Joon Oh
    Kim, Seung Tae
    Lim, Do Hyoung
    Lee, Jeeyun
    Jang, Kee-Taek
    Choi, Yoon-La
    Jang, Hey-Lim
    Park, Se Hoon
    Park, Young Suk
    Lim, Ho Ho
    Kang, Won Ki
    CANCER RESEARCH, 2011, 71
  • [46] Pathologic down-staging following standard (SD) MVAC (methotrexate-vinblastine-doxorubicine-cisplatin) or dose-dense MVAC (DD) neoadjuvant chemotherapy (NC) for muscle-invasive urothelial bladder cancer (UC): A An retrospective multicenter cohort of the French Genitourinary Look Tumor Group (GETUG/AFU).
    Pouessel, Damien
    Chevret, Sylvie
    Bompas, Emmanuelle
    Boudin, Laurys
    Joly, Charlotte A.
    Grellety, Thomas
    Terrisse, Safae Aarab
    Boyle, Helen Jane
    Roubaud, Guilhem
    Chevreau, Christine
    Dauba, Jerome
    Moriceau, Guillaume
    Alexandre, Ingrid
    Deplanque, Gael
    Chapelle, Angelique
    Vauleon, Elodie
    Colau, Alexandre
    Audenet, Francois
    Culine, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] NEMIO: A randomized phase I-II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) plus durvalumab plus /- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
    Thibault, C.
    Elaidi, R. T.
    Pouessel, D.
    Flechon, A.
    Borchiellini, D.
    Barthelemy, P.
    Huillard, O.
    Rouabah, M.
    Braychenko, E.
    Helali, I.
    Audenet, F.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S723 - S723
  • [48] Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG/AFU VESPER V05 phase III trial
    Pfister, C.
    Gravis, G.
    Flechon, A.
    Chevreau, C. M.
    Mahammedi, H.
    Laguerre, B.
    Guillot, A.
    Joly, F.
    Soulie, M.
    Allory, Y.
    Harter, V.
    Culine, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S678 - S678
  • [49] Gene expression profiling in the context of neoadjuvant chemotherapy with DDMVAC plus B (dose dense methotrexate, vinblastine, doxorubicin, cisplatin, and bevacizumab) can predict clinical outcomes and tumor biology
    Siefker-Radtke, Arlene O.
    Choi, Woonyoung
    Melquist, John
    Shen, Yu
    Kamat, Ashish
    Matin, Surena
    Millikan, Randall
    Dinney, Colin P.
    Czernial, Bodgan A.
    McConkey, David J.
    CANCER RESEARCH, 2014, 74 (19)
  • [50] Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses
    Culine, Stephane
    Gravis, Gwenaelle
    Flechon, Aude
    Soulie, Michel
    Guy, Laurent
    Laguerre, Brigitte
    Mottet, Nicolas
    Joly, Florence
    Allory, Yves
    Harter, Valentin
    Pfister, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345